Standard BioTools

LAB

Medical - Equipment & Services · Healthcare

Price

$0.67

+0.02 (+3.51%)

Market Cap

$261.9M

Exchange

NASDAQ

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+403.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 75.8M (2021) → 381.6M (2025)

Winston Score History

The full picture

Standard BioTools makes scientific instruments and software used by researchers in biology and medicine. Its main products include mass cytometry and microfluidics systems, which help scientists study cells in great detail — useful for things like cancer research, drug development, and immune system studies. The company sells primarily to academic research labs, pharmaceutical companies, and biotech firms around the world.

Standard BioTools earns money by selling instruments upfront and then generating recurring revenue from consumables, reagents, and service contracts that customers need to keep using the equipment. It operates globally, with a significant presence in North America, Europe, and Asia. The company was formed through a merger of Fluidigm and SomaLogic in 2023 and is still working to integrate those businesses and cut costs — its deeply negative operating margin reflects that ongoing challenge. The key risk is whether management can reach profitability before the company burns through its remaining cash.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-7.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+22.2% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$26M/ year

↓ Declining (-58% vs prior year)

30.5% of revenue

1.7x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

89.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~2 years

$544M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$544M cash & investments at current burn rate

Revenue declining

Standard BioTools's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

52.4%

Healthy — 52.4% gross margin

Profit after running costs

Operating Margin

-126.3%

Losing money on operations — -126.3%

Return on the money invested

ROCE

-14.8%

Weak — -14.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-36.7%

Shrinking sales (-36.7% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-153.4%

Burning cash (-153.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial